Clinical Trial Detail

NCT ID NCT03761225
Title Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer
Recruitment Recruiting
Gender male
Phase Phase III
Variant Requirements No
Sponsors AB Science
Indications

prostate cancer

Therapies

Docetaxel + Prednisone

Docetaxel + Masitinib + Prednisone

Age Groups: adult senior

No variant requirements are available.